Vancomycin-resistant Enterococci (VRE) are important nosocomial infection agents which have become widespread in recent years. The legal obligation to establish hospital infection control committees and increase in monitoring studies in Turkey has generalized VRE notifications. The treatment options for VRE-induced infections are limited. This study was conducted to identify the molecular epidemiology of the VRE sources found in the study hospital, and to determine the resistance of these strains to various antibiotics. The study was carried out on strains isolated in the microbiology laboratory of Şahinbey Research and Application Hospital, University of Gaziantep. Strains were identified at species level via conventional methods and a fully automated Vitek 2 (Biomerieux, France) identification system. Vancomycin sensitivity was tested via disc diffusion method and E-test (AB Biodisc) strips. Resistance genes of these strains were analyzed via PCR method using GeneOhm VanR (Becton Dickinson, Canada) moleculer tests. In vitro antibacterial efficiency of linezolid, dalfopristin, gentamicin, streptomycin and imipenem was analyzed via the disc diffusion method. All 81 strains included in the study were identified as Enterococcus faecium. VanA gene-type resistance was recorded in 76 (93.8%); vanB gene-type resistance in 2 (2.5%); and nonA-nonB type resistance in 3 (3.7%) of the study strains. No resistance was detected in any of the linezolid and dalfopristine strains. 75 VRE strains (92.6%) were found to be resistant to gentamicin, 28 strains (34.6%) to streptomycin and 79 strains (97.5%) to imipenem. Linezolid and dalfopristin were found to have complete in vitro efficiency against VRE strains, while these strains were found to be highly resistant to other antibiotics tested in the scope of the study. Since treatment of VRE-induced infections is relatively difficult, it is suggested that careful implementation of preventive measures is of great importance to patients in the fight against this agent. Keywords: Antibacterial susceptibility; enterococci; resistance gene; vancomycin
Introduction
Enterococci are present in the gastrointestinal system as normal flora elements. Enterococci have gained gradual importance as nosocomial pathogens in the last two decades, as they have developed resistance to the majority of widely-used antibiotics (1, 2) . In the hospital environment, Enterococci are isolated from surfaces, the hands of hospital personnel and medical equipment (3) . Enterococci have intrinsic resistance to low-level penicillin and low-level aminoglycosides, trimethoprimsulfamethaxazole, fluoroquinolone and lincosamide. They have also developed resistance to many other antibiotic groups via transmission of genetic material or via mutation (4, 5) . Among these resistances, the most clinically important one is the resistance developed against glycopeptides. Vancomycin resistance among Enterococci (VRE) was first notified in England in 1988, and similar notifications were subsequently made in European countries and the USA (6) . CDC and the National Nosocomial Infections Surveillance declared that 30% of the Enterococci infections recorded in 2001 were caused by vancomycin-resistant strains (2) . The widespread use of vancomycin and wide-spectrum cephalosporin contributed greatly to the rapid spread of VRE strains (7, 8) . In addition, avoparcin, which is a derivative of glycopeptides and is used as animal feed particularly in Europe, is believed to have an important role in the generalization of vancomycin resistance in Enterococci (9, 10) . Glycopeptide antibiotics affect Gram positive bacteria by damaging peptidogylcan synthesis and, in turn, cell wall synthesis (4). Five phenotypes have been identified as having resistance to this group of antibiotics: VanA, VanB, VanC, VanD and VanE phenotypes. Phenotypical naming is made on the basis of the resistance of the Enterococci strain to vancomycin and teicoplanin, the inductivity capacity of the resistance and the capacity of transferability of the resistance to other bacteria (4) . VanA phenotype is the most common phenotype, and results in the development of high-level vancomycin and teicoplanin resistance. The most important characteristic of the resistance developed by VanA and VanB phenotypes is the inductivity and transferability (via plasmid) of the resistance (4,9). Molecular typing of VRE resistance genes is important in determination of microbial spread and use of infection control procedures. The present study was conducted to detect the molecular epidemiology of the isolated VRE strains and to analyze the in vitro efficiency of some antibiotics against these strains.
Material and Methods
This prospective study was conducted between January 2009 and August 2010 on Enterococci strains isolated from in-patients of the 800-bed capacity research hospital of the Faculty of Medicine, University of Gaziantep. Bacteria were isolated from samples sent to the laboratory for routine bacteriological examination, and from samples collected for monitoring.
Bacteriological Identification:
Bacteria were identified by using a fully-automated Vitek2 bacteria identification system. In addition conventional methods were used, if necessary (11).
Blood culture samples were treated in fully-automated BacT ALERT 3D (Biomerieux, France) blood culture bottles.
Sensitivity Test:
Vancomycin resistance was analyzed using E test (AB Biodisc) strips, in compliance with the CLSI standards. The in vitro antibacterial efficiency of linezolid (30 µg, Oxoid), dalfopristin (15 µg, Oxoid) and imipenem (10 µg, Oxoid) was analyzed via the disc diffusion method, in compliance with the CLSI standards. 120 µg and 300 µg antibiotic discs were used to detect high-level resistance to gentamicin and streptomycin, respectively.
Molecular:
Fresh cultures of bacteria found to be conventionally vancomycin-resistant were subjected to a BD GeneOhm VanR test in order to detect resistance genes. The kits used in these tests were the ready-to-use commercial kits designed to detect the vancomycin resistance of enterococci. Specific probes were used to detect VanA, VanB genes, which are responsible for vancomycin resistance. Other non-detected phenotypes are reported as nonA-non-B and, when there is no gene that develops vancomycin resistance, the sample is reported to be negative. After the sample lysis, vanA and vanB genetic regions (if any) were amplified and read using a SmartCyler PCR device.
Results
The present study was conducted on 81 stains, 44 of which were obtained from rectal swab samples collected for surveillance and 37 of which were from laboratory samples collected for routine identification. Distribution of the strains according to type and clinic is given in Table 1 . Neonatal Gastroenterology
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Rectal swab 22 Each of the 81 strains included in the study was identified as E. faecium. Distribution of the resistance genes detected in these isolates is given in Table 2 .
tests. Seventy-five VRE strains (92.6%) were found to be resistant to gentamicin, 28 strains (34.6%) to streptomycin and 79 strains (97.5%) to imipenem (Table  3) . (12) . Vancomycin is effective in the treatment of multiresistant Enterococci infections; however, VRE notifications were first made in England and France in 1988, followed by increasingly common notifications of resistance globally (6, 13) . The first VRE notification in Turkey occurred in 1998 (14) , since when the number of VRE notifications has rapidly increased (15) . VRE, which had never been recorded in our hospital until recent years, was isolated from 81 patients during the study period. In addition, 57 of the study strains were isolated from two clinics, with 32 (70.4%) isolated from pediatric oncology hematology and 25 from the intensive care unit of the internal diseases clinic. Thirtyfive of the strains isolated from these two clinics were isolated from rectal swab samples collected for surveillance. With the increase in the vancomycinresistance of Enterococci, the CDC's "Hospital Infection Control Practices Advisory Committee" (HICPAC) issued a "suggestions package" in 1995 about the possible measures to be taken to prevent nosocomial VRE dispersion (16) . One of the suggestions was that, where a VRE case is detected, surveillance cultures should be collected from each patient in the same room and service as the infected person, in order to detect colonized patients and to ensure insulation. As is the case in many other health centers, VRE isolation has increased in the study hospital following the application of such measures. In many patients, VRE is detected only in colonized form. However, some centers which have reported a colonized/infected patient ratio of 10:1 (17, 18) .
E. faecalis is the most frequently isolated clinical Enterococci; however, E. faecium species develop highlevel vancomycin resistance (19) . The ratio of E. faecalis to E. faecium has recently decreased from 3.7:1 to 1.9:1, particularly in blood culture sources (19) . All of the strains isolated in the scope of the present study were identified as E. faecium. Nearly 94% of the detected strains were found to have VanA-type glycopeptides resistance. Similar results have been produced by many studies conducted in Turkey (15, (20) (21) (22) . The present study differs from such studies in terms of the high number of Enterococci analyzed. Accordingly, the data obtained in this study were found to be epidemiologically meaningful, at least for the study hospital. Zer et al. (23) conducted a study at the present study hospital in 2002, followed by Ekşi (24) in 2008; neither of these previous studies detected vancomycin resistance in the Enterococci isolated in the scope of their studies. A study in 2007 by Menteş et al. (25) detected vancomycin resistance in 4 of 126 Enterococci strains and identified them as VanA genotype. A significant increase has been observed in the number of VRE detections in our hospital. This increase, as emphasized, may be related to the increased isolation rate due to infection prevention applications, and to the increased number of the patients monitored in our hospital. Resistance to glycopeptides has necessitated the use of other drug options in the treatment of Enterococci-induced infections. Linezolid is an oxazolidine-type antibiotic and is a ribosomal protein synthesis inhibitor in bacteria (26) . Linezolid is granted a primary use permit for VRE infections (27) . Linezolid is observed to be very effective against VRE strains. Most of the studies conducted on this drug have revealed no resistance (28) (29) (30) ; however, some resistant VRE strains have been reported (31, 32) . No linezoid resistance was recorded in the present study. Another antibiotic group suggested for the treatment of vancomycin-resistant Enterococci is quinopristin/dalphopristin. This antibiotic is a combination of quinopristin and dalphopristin at a ratio of 30:70 (33) . This antibiotic is reported to be more effective than E. faecalis on E. faecium strains (34) . Some studies have revealed nearly 90% sensitivity (34, 35) . No quinopristin/dalphopristin-resistant strain was detected in the present study. This may be due to the fact that this drug is not approved for sale in Turkey and has not yet been introduced into clinical use. High-level resistance to gentamicin and streptomycin -in the aminoglycoside group antibiotics tested in the studywas recorded as 92.6% and 34.6%, respectively. In a multi-centered study carried out in Turkey, a high-level aminoglycoside resistance (48.1%) was detected (36) . Turkey has the second-highest level of aminoglycoside resistance in Europe. The rates recorded in the present study are found to be relatively high, particularly for gentamicin. This is thought to result from widespread and frequent use of gentamicin in Turkey for other infections, in addition to VRE. This finding may also have resulted from the fact that the present study was conducted on a resistant bacteria type.
The resistance of Enterococci to antibiotics is found to be at alarming levels; it is therefore concluded that it is easier to implement infection control measures than to treat the enterococci-induced infections.
